Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anticoagulants | 72 | 2023 | 4812 | 3.720 |
Why?
|
Thrombophilia | 15 | 2023 | 305 | 2.910 |
Why?
|
Venous Thromboembolism | 27 | 2024 | 1866 | 2.840 |
Why?
|
Venous Thrombosis | 42 | 2020 | 1303 | 2.780 |
Why?
|
Factor VII | 25 | 2010 | 139 | 2.660 |
Why?
|
Factor VII Deficiency | 17 | 2006 | 31 | 2.250 |
Why?
|
Thromboembolism | 34 | 2022 | 995 | 2.080 |
Why?
|
Prothrombin | 41 | 2024 | 191 | 2.020 |
Why?
|
Blood Coagulation | 46 | 2019 | 1154 | 2.000 |
Why?
|
Factor V | 18 | 2024 | 167 | 1.800 |
Why?
|
Polysaccharides | 23 | 2008 | 1014 | 1.640 |
Why?
|
Thrombosis | 34 | 2024 | 2942 | 1.600 |
Why?
|
Fibrinolytic Agents | 19 | 2020 | 2084 | 1.500 |
Why?
|
Thrombin | 34 | 2013 | 591 | 1.480 |
Why?
|
Blood Coagulation Factors | 24 | 2022 | 365 | 1.230 |
Why?
|
Hemorrhage | 25 | 2022 | 3424 | 1.090 |
Why?
|
Hemostasis | 21 | 2023 | 467 | 1.030 |
Why?
|
Antithrombin III Deficiency | 12 | 2017 | 28 | 0.960 |
Why?
|
Enoxaparin | 17 | 2020 | 391 | 0.950 |
Why?
|
Factor VIIa | 15 | 2009 | 103 | 0.930 |
Why?
|
beta-Alanine | 2 | 2015 | 82 | 0.900 |
Why?
|
Hemophilia B | 9 | 2015 | 84 | 0.850 |
Why?
|
Heparin | 15 | 2019 | 1634 | 0.840 |
Why?
|
Antithrombins | 13 | 2013 | 294 | 0.790 |
Why?
|
Warfarin | 21 | 2013 | 1483 | 0.780 |
Why?
|
Hemophilia A | 6 | 2023 | 360 | 0.770 |
Why?
|
Pregnancy Complications, Hematologic | 5 | 2011 | 179 | 0.740 |
Why?
|
Pulmonary Embolism | 15 | 2020 | 2567 | 0.710 |
Why?
|
Heparin, Low-Molecular-Weight | 7 | 2020 | 344 | 0.700 |
Why?
|
Benzimidazoles | 3 | 2015 | 858 | 0.700 |
Why?
|
Antithrombin III | 20 | 2008 | 128 | 0.680 |
Why?
|
Thrombolytic Therapy | 7 | 2020 | 2064 | 0.680 |
Why?
|
Point Mutation | 8 | 2006 | 1595 | 0.670 |
Why?
|
Factor Xa | 15 | 2022 | 167 | 0.650 |
Why?
|
Orthopedic Procedures | 13 | 2004 | 1265 | 0.630 |
Why?
|
Thromboplastin | 14 | 2012 | 286 | 0.610 |
Why?
|
Intracranial Hemorrhage, Traumatic | 2 | 2017 | 54 | 0.610 |
Why?
|
Factor IX | 15 | 2009 | 77 | 0.580 |
Why?
|
Fibrin Fibrinogen Degradation Products | 8 | 2019 | 422 | 0.560 |
Why?
|
Aortic Rupture | 1 | 2019 | 319 | 0.530 |
Why?
|
Protein C | 15 | 1995 | 133 | 0.510 |
Why?
|
Arthroplasty, Replacement, Knee | 9 | 2020 | 1393 | 0.510 |
Why?
|
Biological Products | 1 | 2023 | 914 | 0.470 |
Why?
|
Craniocerebral Trauma | 1 | 2017 | 490 | 0.410 |
Why?
|
Administration, Oral | 13 | 2019 | 4021 | 0.390 |
Why?
|
Morpholines | 6 | 2013 | 581 | 0.390 |
Why?
|
Peptide Fragments | 27 | 2020 | 5112 | 0.380 |
Why?
|
Antidotes | 1 | 2012 | 138 | 0.380 |
Why?
|
Humans | 243 | 2024 | 761504 | 0.380 |
Why?
|
Recombinant Proteins | 17 | 2022 | 6534 | 0.360 |
Why?
|
Thiophenes | 6 | 2013 | 569 | 0.350 |
Why?
|
Diclofenac | 1 | 2010 | 68 | 0.350 |
Why?
|
Factor X | 10 | 2002 | 64 | 0.340 |
Why?
|
Accidental Falls | 2 | 2017 | 1068 | 0.340 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2019 | 1228 | 0.330 |
Why?
|
Factor XI | 4 | 2020 | 34 | 0.330 |
Why?
|
Factor IXa | 6 | 2000 | 19 | 0.330 |
Why?
|
von Willebrand Diseases | 2 | 2023 | 132 | 0.320 |
Why?
|
Monitoring, Physiologic | 4 | 2013 | 1779 | 0.320 |
Why?
|
Protein C Deficiency | 8 | 2004 | 25 | 0.320 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2010 | 361 | 0.320 |
Why?
|
Homozygote | 7 | 2020 | 1776 | 0.310 |
Why?
|
Polymorphism, Genetic | 7 | 2010 | 4243 | 0.310 |
Why?
|
Blood Coagulation Disorders | 8 | 2021 | 350 | 0.310 |
Why?
|
Coronary Disease | 13 | 2010 | 5914 | 0.270 |
Why?
|
Fibrinopeptide A | 16 | 2004 | 43 | 0.270 |
Why?
|
Promoter Regions, Genetic | 5 | 2003 | 5789 | 0.260 |
Why?
|
Thrombophlebitis | 9 | 1994 | 289 | 0.260 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2017 | 2751 | 0.260 |
Why?
|
Risk Factors | 46 | 2024 | 74206 | 0.260 |
Why?
|
Risk | 12 | 2020 | 9610 | 0.250 |
Why?
|
Atrial Fibrillation | 7 | 2013 | 5127 | 0.250 |
Why?
|
Heterozygote | 6 | 2024 | 2787 | 0.250 |
Why?
|
Factor VIII | 8 | 2023 | 348 | 0.240 |
Why?
|
Male | 118 | 2024 | 360804 | 0.230 |
Why?
|
Genetic Testing | 5 | 2010 | 3537 | 0.230 |
Why?
|
Vitamin K | 3 | 2013 | 318 | 0.230 |
Why?
|
Stroke | 8 | 2013 | 9757 | 0.230 |
Why?
|
Hemostatics | 3 | 2023 | 241 | 0.230 |
Why?
|
von Willebrand Disease, Type 2 | 1 | 2023 | 7 | 0.230 |
Why?
|
Female | 102 | 2024 | 392644 | 0.220 |
Why?
|
5' Flanking Region | 1 | 2003 | 31 | 0.220 |
Why?
|
Drug Administration Schedule | 12 | 2019 | 4853 | 0.220 |
Why?
|
Guidelines as Topic | 1 | 2010 | 1386 | 0.220 |
Why?
|
Recurrence | 14 | 2019 | 8465 | 0.210 |
Why?
|
Disseminated Intravascular Coagulation | 12 | 2002 | 186 | 0.210 |
Why?
|
Receptors, Steroid | 1 | 2003 | 156 | 0.210 |
Why?
|
Patient Care Team | 3 | 2020 | 2521 | 0.200 |
Why?
|
Phosphoproteins | 3 | 2003 | 2448 | 0.200 |
Why?
|
Middle Aged | 88 | 2024 | 220895 | 0.190 |
Why?
|
Postoperative Complications | 15 | 2004 | 15631 | 0.190 |
Why?
|
Myocardial Ischemia | 3 | 2004 | 2113 | 0.180 |
Why?
|
Postthrombotic Syndrome | 1 | 2020 | 28 | 0.180 |
Why?
|
Mutation | 17 | 2004 | 30052 | 0.180 |
Why?
|
Mutagenesis, Insertional | 2 | 2001 | 656 | 0.180 |
Why?
|
Blood Platelets | 3 | 2010 | 2479 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5315 | 0.180 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2273 | 0.180 |
Why?
|
Hematoma, Subdural, Spinal | 1 | 2020 | 8 | 0.180 |
Why?
|
Thrombocytopenia | 3 | 2008 | 1181 | 0.180 |
Why?
|
Blood Coagulation Tests | 9 | 2018 | 271 | 0.180 |
Why?
|
Patient Selection | 2 | 2020 | 4244 | 0.180 |
Why?
|
Aged | 63 | 2024 | 169289 | 0.180 |
Why?
|
Algorithms | 1 | 2020 | 14031 | 0.170 |
Why?
|
Knee | 1 | 2001 | 279 | 0.170 |
Why?
|
Hematoma, Epidural, Spinal | 1 | 2020 | 37 | 0.170 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 3810 | 0.170 |
Why?
|
Injections, Subcutaneous | 7 | 2009 | 681 | 0.170 |
Why?
|
Embolectomy | 1 | 2020 | 129 | 0.160 |
Why?
|
DNA-Binding Proteins | 3 | 2003 | 9606 | 0.160 |
Why?
|
Quercetin | 1 | 2019 | 97 | 0.160 |
Why?
|
Biological Specimen Banks | 1 | 2024 | 783 | 0.160 |
Why?
|
Intraoperative Period | 1 | 2019 | 510 | 0.150 |
Why?
|
Plasminogen | 4 | 2008 | 144 | 0.150 |
Why?
|
Vena Cava Filters | 2 | 2020 | 261 | 0.150 |
Why?
|
Pregnancy | 17 | 2017 | 29874 | 0.150 |
Why?
|
Sp1 Transcription Factor | 1 | 1998 | 140 | 0.150 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2018 | 71 | 0.150 |
Why?
|
Genotype | 11 | 2024 | 12990 | 0.150 |
Why?
|
3' Untranslated Regions | 2 | 2001 | 519 | 0.150 |
Why?
|
Adult | 64 | 2024 | 221177 | 0.150 |
Why?
|
Neoplasms | 11 | 2020 | 22170 | 0.150 |
Why?
|
Binding Sites | 6 | 2003 | 6055 | 0.150 |
Why?
|
Angina, Unstable | 5 | 2003 | 888 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2007 | 857 | 0.140 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1462 | 0.140 |
Why?
|
Protein Disulfide-Isomerases | 1 | 2019 | 208 | 0.140 |
Why?
|
Fibrinogen | 9 | 2009 | 888 | 0.140 |
Why?
|
Time Factors | 20 | 2019 | 39967 | 0.140 |
Why?
|
Acute Disease | 5 | 2020 | 7237 | 0.140 |
Why?
|
Glycoproteins | 6 | 2005 | 2203 | 0.140 |
Why?
|
Radioimmunoassay | 11 | 2002 | 862 | 0.140 |
Why?
|
Transcription Factors | 3 | 2003 | 12128 | 0.140 |
Why?
|
Hormone Replacement Therapy | 1 | 2002 | 751 | 0.140 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2016 | 513 | 0.130 |
Why?
|
Pyridones | 2 | 2013 | 809 | 0.130 |
Why?
|
Colistin | 1 | 2016 | 44 | 0.130 |
Why?
|
Hepatocyte Nuclear Factor 4 | 3 | 2003 | 126 | 0.130 |
Why?
|
Arthroplasty, Replacement, Hip | 7 | 2008 | 1413 | 0.130 |
Why?
|
Mutation, Missense | 3 | 2006 | 2571 | 0.130 |
Why?
|
Organ Specificity | 1 | 2020 | 1967 | 0.130 |
Why?
|
Double-Blind Method | 17 | 2019 | 12341 | 0.120 |
Why?
|
Abortion, Spontaneous | 2 | 2011 | 533 | 0.120 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3712 | 0.120 |
Why?
|
Hemarthrosis | 1 | 2015 | 39 | 0.120 |
Why?
|
Transfection | 6 | 2005 | 5774 | 0.120 |
Why?
|
Biological Availability | 3 | 2011 | 390 | 0.120 |
Why?
|
Incidence | 12 | 2020 | 21353 | 0.120 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13380 | 0.120 |
Why?
|
Thrombelastography | 1 | 2017 | 187 | 0.120 |
Why?
|
Gram-Negative Bacteria | 1 | 2016 | 272 | 0.120 |
Why?
|
Factor VIIIa | 3 | 1995 | 16 | 0.120 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2016 | 238 | 0.110 |
Why?
|
Complement C1 Inhibitor Protein | 1 | 2014 | 97 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2013 | 10209 | 0.110 |
Why?
|
Fibrinolysis | 6 | 1995 | 332 | 0.110 |
Why?
|
DNA Mutational Analysis | 6 | 2001 | 4111 | 0.110 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2003 | 318 | 0.110 |
Why?
|
Poland | 3 | 2000 | 198 | 0.110 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 316 | 0.110 |
Why?
|
Haplotypes | 3 | 2010 | 2713 | 0.110 |
Why?
|
Treatment Failure | 1 | 2019 | 2645 | 0.110 |
Why?
|
Blood Proteins | 3 | 2004 | 1173 | 0.110 |
Why?
|
Pedigree | 12 | 2000 | 4542 | 0.110 |
Why?
|
Factor XIa | 3 | 2000 | 8 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3084 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3204 | 0.100 |
Why?
|
Heparitin Sulfate | 2 | 2008 | 223 | 0.100 |
Why?
|
Review Literature as Topic | 1 | 2014 | 348 | 0.100 |
Why?
|
Heat-Shock Proteins | 1 | 1996 | 795 | 0.100 |
Why?
|
Thrombectomy | 1 | 2017 | 705 | 0.100 |
Why?
|
Codon | 3 | 2000 | 601 | 0.100 |
Why?
|
Hematology | 1 | 2016 | 243 | 0.100 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 1992 | 25 | 0.100 |
Why?
|
Transcription, Genetic | 2 | 2003 | 7594 | 0.100 |
Why?
|
Cricetinae | 4 | 2005 | 2423 | 0.100 |
Why?
|
Treatment Outcome | 18 | 2019 | 64680 | 0.100 |
Why?
|
Leukemia, Hairy Cell | 1 | 1992 | 82 | 0.100 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2016 | 587 | 0.100 |
Why?
|
Drug Evaluation | 2 | 2010 | 641 | 0.100 |
Why?
|
Trauma Centers | 1 | 2017 | 937 | 0.100 |
Why?
|
Splenic Neoplasms | 1 | 1992 | 94 | 0.100 |
Why?
|
Meta-Analysis as Topic | 2 | 2009 | 1380 | 0.100 |
Why?
|
Immunoassay | 2 | 2005 | 745 | 0.090 |
Why?
|
Abortion, Habitual | 2 | 2009 | 61 | 0.090 |
Why?
|
Prodrugs | 1 | 2013 | 261 | 0.090 |
Why?
|
Contraceptive Agents, Female | 1 | 2012 | 118 | 0.090 |
Why?
|
Pyrazoles | 2 | 2013 | 2009 | 0.090 |
Why?
|
Helminth Proteins | 2 | 2002 | 173 | 0.090 |
Why?
|
Receptors, Cell Surface | 5 | 2009 | 2822 | 0.090 |
Why?
|
Aged, 80 and over | 20 | 2020 | 58976 | 0.090 |
Why?
|
International Normalized Ratio | 4 | 2006 | 382 | 0.090 |
Why?
|
CHO Cells | 3 | 1999 | 1387 | 0.090 |
Why?
|
Phlebography | 3 | 2009 | 326 | 0.090 |
Why?
|
Progestins | 1 | 2012 | 301 | 0.090 |
Why?
|
Oligopeptides | 5 | 1988 | 1187 | 0.090 |
Why?
|
Enzyme Activation | 10 | 2007 | 3597 | 0.090 |
Why?
|
Myocardial Infarction | 9 | 2006 | 11460 | 0.090 |
Why?
|
Blood Specimen Collection | 1 | 1991 | 238 | 0.090 |
Why?
|
Ketorolac | 1 | 2010 | 94 | 0.090 |
Why?
|
Hematoma | 1 | 2015 | 768 | 0.090 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1989 | 38 | 0.090 |
Why?
|
Abruptio Placentae | 1 | 2011 | 118 | 0.080 |
Why?
|
Injections, Intravenous | 2 | 2010 | 1379 | 0.080 |
Why?
|
Leg | 1 | 2014 | 1088 | 0.080 |
Why?
|
Genes, Reporter | 2 | 2003 | 1529 | 0.080 |
Why?
|
Antiphospholipid Syndrome | 1 | 2011 | 165 | 0.080 |
Why?
|
Coagulation Protein Disorders | 1 | 2008 | 6 | 0.080 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2013 | 774 | 0.080 |
Why?
|
Men's Health | 1 | 2009 | 73 | 0.080 |
Why?
|
Platelet Count | 2 | 2010 | 781 | 0.080 |
Why?
|
Coronary Artery Bypass | 2 | 2017 | 2188 | 0.080 |
Why?
|
Platelet Function Tests | 1 | 2010 | 271 | 0.080 |
Why?
|
Reference Values | 9 | 2009 | 4920 | 0.080 |
Why?
|
Societies, Medical | 3 | 2018 | 3905 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2548 | 0.080 |
Why?
|
Polymerase Chain Reaction | 6 | 2004 | 6075 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2024 | 15936 | 0.080 |
Why?
|
Kallikrein-Kinin System | 1 | 2007 | 9 | 0.070 |
Why?
|
Predictive Value of Tests | 5 | 2019 | 15266 | 0.070 |
Why?
|
Prothrombin Time | 5 | 2008 | 117 | 0.070 |
Why?
|
Gingivitis | 1 | 2008 | 124 | 0.070 |
Why?
|
Stillbirth | 1 | 2011 | 368 | 0.070 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2007 | 28 | 0.070 |
Why?
|
Consanguinity | 2 | 2001 | 456 | 0.070 |
Why?
|
Immunoenzyme Techniques | 3 | 2007 | 1705 | 0.070 |
Why?
|
Structure-Activity Relationship | 3 | 2003 | 3076 | 0.070 |
Why?
|
Antibodies | 2 | 2015 | 2418 | 0.070 |
Why?
|
Critical Illness | 2 | 2021 | 2723 | 0.070 |
Why?
|
Triglycerides | 4 | 2007 | 2461 | 0.070 |
Why?
|
Alleles | 5 | 2010 | 6863 | 0.070 |
Why?
|
Arginine | 4 | 2008 | 934 | 0.070 |
Why?
|
Patient Discharge | 1 | 2020 | 3443 | 0.070 |
Why?
|
Clinical Trials as Topic | 6 | 2013 | 8002 | 0.070 |
Why?
|
Aging | 5 | 2013 | 8708 | 0.070 |
Why?
|
Epinephrine | 1 | 2010 | 792 | 0.070 |
Why?
|
Hospital Mortality | 2 | 2020 | 5294 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3600 | 0.070 |
Why?
|
Surgical Procedures, Operative | 3 | 2007 | 1922 | 0.070 |
Why?
|
Case-Control Studies | 9 | 2009 | 22176 | 0.070 |
Why?
|
Antigens | 3 | 2005 | 1443 | 0.070 |
Why?
|
Adolescent | 23 | 2020 | 88319 | 0.070 |
Why?
|
von Willebrand Factor | 4 | 2023 | 673 | 0.070 |
Why?
|
Area Under Curve | 1 | 2010 | 1638 | 0.070 |
Why?
|
Endotoxins | 2 | 2002 | 520 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2010 | 2078 | 0.070 |
Why?
|
Prospective Studies | 14 | 2019 | 54425 | 0.070 |
Why?
|
Cause of Death | 3 | 2020 | 3683 | 0.070 |
Why?
|
Base Sequence | 6 | 1998 | 12441 | 0.070 |
Why?
|
Live Birth | 1 | 2009 | 511 | 0.070 |
Why?
|
Italy | 2 | 1999 | 842 | 0.060 |
Why?
|
Drug Delivery Systems | 2 | 2007 | 2226 | 0.060 |
Why?
|
Cricetulus | 2 | 1997 | 814 | 0.060 |
Why?
|
Pennsylvania | 1 | 2006 | 613 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 1994 | 4352 | 0.060 |
Why?
|
Coagulants | 1 | 2004 | 45 | 0.060 |
Why?
|
Cardiology | 1 | 2016 | 1656 | 0.060 |
Why?
|
Hematoma, Epidural, Cranial | 1 | 2004 | 59 | 0.060 |
Why?
|
Hirudins | 2 | 2008 | 179 | 0.060 |
Why?
|
Thrombospondin 1 | 1 | 2006 | 257 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 2004 | 82 | 0.060 |
Why?
|
Platelet Factor 4 | 1 | 2004 | 129 | 0.060 |
Why?
|
Retrospective Studies | 8 | 2022 | 80636 | 0.060 |
Why?
|
Molecular Epidemiology | 1 | 2006 | 469 | 0.060 |
Why?
|
Coumarins | 2 | 1995 | 118 | 0.060 |
Why?
|
Postpartum Hemorrhage | 1 | 2008 | 271 | 0.060 |
Why?
|
Risk Assessment | 9 | 2020 | 23995 | 0.060 |
Why?
|
COUP Transcription Factors | 1 | 2003 | 4 | 0.060 |
Why?
|
Exons | 2 | 2003 | 2391 | 0.060 |
Why?
|
Hospitals | 1 | 2017 | 3882 | 0.060 |
Why?
|
Prognosis | 5 | 2020 | 29625 | 0.060 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 7390 | 0.050 |
Why?
|
COUP Transcription Factor II | 1 | 2003 | 18 | 0.050 |
Why?
|
DNA, Complementary | 2 | 1997 | 1991 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2019 | 10766 | 0.050 |
Why?
|
Cloning, Molecular | 2 | 2001 | 4174 | 0.050 |
Why?
|
Genetic Markers | 1 | 2009 | 2601 | 0.050 |
Why?
|
Intracranial Embolism and Thrombosis | 2 | 1993 | 144 | 0.050 |
Why?
|
Genital Diseases, Female | 1 | 2004 | 192 | 0.050 |
Why?
|
Factor XI Deficiency | 2 | 1994 | 16 | 0.050 |
Why?
|
Cerebral Hemorrhage | 2 | 2013 | 2656 | 0.050 |
Why?
|
Animals | 23 | 2014 | 168459 | 0.050 |
Why?
|
Hormones | 1 | 2006 | 869 | 0.050 |
Why?
|
Follow-Up Studies | 10 | 2020 | 39106 | 0.050 |
Why?
|
Curriculum | 1 | 2016 | 3743 | 0.050 |
Why?
|
Collagen | 1 | 2010 | 2638 | 0.050 |
Why?
|
Selectins | 1 | 2002 | 101 | 0.050 |
Why?
|
Bleomycin | 1 | 1983 | 494 | 0.050 |
Why?
|
Protein S | 4 | 1992 | 30 | 0.050 |
Why?
|
Aspirin | 3 | 2010 | 3133 | 0.050 |
Why?
|
Young Adult | 6 | 2020 | 59243 | 0.050 |
Why?
|
Response Elements | 1 | 2003 | 309 | 0.050 |
Why?
|
DNA | 6 | 2005 | 7212 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2009 | 5869 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2011 | 1231 | 0.050 |
Why?
|
Angina Pectoris | 3 | 2000 | 959 | 0.050 |
Why?
|
Asparaginase | 1 | 1983 | 240 | 0.050 |
Why?
|
HeLa Cells | 2 | 1998 | 3093 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 1989 | 3613 | 0.050 |
Why?
|
Antigens, CD | 2 | 2009 | 4003 | 0.050 |
Why?
|
Pentachlorophenol | 1 | 2001 | 10 | 0.050 |
Why?
|
Abdomen | 1 | 2007 | 1128 | 0.050 |
Why?
|
Receptors, Glucocorticoid | 1 | 2003 | 305 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2013 | 4016 | 0.050 |
Why?
|
Base Pair Mismatch | 1 | 2001 | 92 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8224 | 0.050 |
Why?
|
Prevalence | 5 | 2013 | 15732 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2003 | 18965 | 0.050 |
Why?
|
Peptide Hydrolases | 2 | 2002 | 624 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 6 | 2024 | 17904 | 0.050 |
Why?
|
Tissue Plasminogen Activator | 2 | 2001 | 1164 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2003 | 629 | 0.050 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1626 | 0.050 |
Why?
|
Introns | 1 | 2003 | 981 | 0.050 |
Why?
|
Critical Care | 1 | 2013 | 2696 | 0.040 |
Why?
|
Hydrogen Bonding | 1 | 2001 | 291 | 0.040 |
Why?
|
Polymorphism, Single-Stranded Conformational | 2 | 2004 | 329 | 0.040 |
Why?
|
Family | 2 | 2010 | 3194 | 0.040 |
Why?
|
Cohort Studies | 8 | 2016 | 41487 | 0.040 |
Why?
|
Clinical Competence | 1 | 2016 | 4792 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2001 | 277 | 0.040 |
Why?
|
Molecular Sequence Data | 5 | 1996 | 17635 | 0.040 |
Why?
|
Cross Reactions | 1 | 2001 | 817 | 0.040 |
Why?
|
Blood Coagulation Factor Inhibitors | 1 | 1999 | 14 | 0.040 |
Why?
|
Protein S Deficiency | 2 | 1996 | 13 | 0.040 |
Why?
|
Binding, Competitive | 1 | 2000 | 1141 | 0.040 |
Why?
|
Inflammation | 5 | 2020 | 10773 | 0.040 |
Why?
|
Factor V Deficiency | 2 | 1996 | 10 | 0.040 |
Why?
|
Disease Susceptibility | 4 | 2007 | 1787 | 0.040 |
Why?
|
Models, Statistical | 3 | 2009 | 5079 | 0.040 |
Why?
|
Withholding Treatment | 2 | 2015 | 617 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 2691 | 0.040 |
Why?
|
Sex Factors | 4 | 2019 | 10552 | 0.040 |
Why?
|
Frameshift Mutation | 1 | 2000 | 392 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2000 | 779 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2001 | 1624 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2008 | 1998 | 0.040 |
Why?
|
Protein Structure, Tertiary | 2 | 2006 | 3792 | 0.040 |
Why?
|
Partial Thromboplastin Time | 2 | 2001 | 204 | 0.040 |
Why?
|
Endothelium, Vascular | 3 | 2020 | 4431 | 0.040 |
Why?
|
Pesticides | 1 | 2001 | 296 | 0.040 |
Why?
|
Nuclear Family | 1 | 1999 | 311 | 0.040 |
Why?
|
Biomedical Research | 1 | 2013 | 3429 | 0.040 |
Why?
|
Pyridines | 1 | 2010 | 2875 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 413 | 0.040 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2018 | 110 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2006 | 6814 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2020 | 20570 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7407 | 0.040 |
Why?
|
Valine | 1 | 1999 | 408 | 0.040 |
Why?
|
Dietary Fats | 3 | 2007 | 1995 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7879 | 0.040 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1999 | 239 | 0.040 |
Why?
|
Jews | 1 | 1999 | 356 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 1989 | 3617 | 0.040 |
Why?
|
Safety | 1 | 2002 | 1150 | 0.040 |
Why?
|
Decision Making | 1 | 2011 | 3929 | 0.030 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2001 | 547 | 0.030 |
Why?
|
Acute Coronary Syndrome | 1 | 2010 | 2190 | 0.030 |
Why?
|
Hip Fractures | 2 | 2002 | 988 | 0.030 |
Why?
|
Pan troglodytes | 4 | 2002 | 223 | 0.030 |
Why?
|
Infusions, Parenteral | 2 | 2008 | 397 | 0.030 |
Why?
|
Alanine | 1 | 1999 | 609 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 497 | 0.030 |
Why?
|
Ultrasonography | 1 | 2010 | 5972 | 0.030 |
Why?
|
Lipids | 1 | 2007 | 3341 | 0.030 |
Why?
|
Basal Metabolism | 1 | 1997 | 161 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2000 | 1738 | 0.030 |
Why?
|
Antibody Formation | 1 | 2001 | 1395 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 1999 | 701 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2021 | 1125 | 0.030 |
Why?
|
Myositis | 1 | 1979 | 271 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2007 | 2921 | 0.030 |
Why?
|
Saphenous Vein | 1 | 1999 | 516 | 0.030 |
Why?
|
Myeloproliferative Disorders | 1 | 2002 | 613 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 1992 | 4320 | 0.030 |
Why?
|
Cerebrovascular Disorders | 2 | 1993 | 1474 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 4511 | 0.030 |
Why?
|
Homocysteine | 1 | 1999 | 638 | 0.030 |
Why?
|
COS Cells | 1 | 1997 | 1130 | 0.030 |
Why?
|
Estrogen Replacement Therapy | 2 | 2012 | 1208 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 737 | 0.030 |
Why?
|
Streptokinase | 1 | 1995 | 186 | 0.030 |
Why?
|
Fibrin | 4 | 1995 | 507 | 0.030 |
Why?
|
Evidence-Based Medicine | 3 | 2018 | 3688 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2020 | 726 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2020 | 565 | 0.030 |
Why?
|
Bloodletting | 1 | 1995 | 22 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 4740 | 0.030 |
Why?
|
Stockings, Compression | 1 | 2015 | 36 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2005 | 12463 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12725 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2001 | 1560 | 0.030 |
Why?
|
Postprandial Period | 1 | 1996 | 315 | 0.030 |
Why?
|
Isotonic Solutions | 1 | 1995 | 117 | 0.030 |
Why?
|
Hemodilution | 1 | 1995 | 120 | 0.030 |
Why?
|
Purpura | 1 | 1995 | 117 | 0.030 |
Why?
|
Coronary Artery Disease | 3 | 2007 | 6403 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 822 | 0.030 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2020 | 628 | 0.030 |
Why?
|
Genetic Variation | 1 | 2009 | 6567 | 0.030 |
Why?
|
Blood Component Transfusion | 1 | 1995 | 142 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 1999 | 746 | 0.030 |
Why?
|
Cardiovascular Diseases | 3 | 2007 | 15500 | 0.030 |
Why?
|
Polycythemia | 1 | 1995 | 124 | 0.030 |
Why?
|
Pentoxifylline | 1 | 1994 | 53 | 0.030 |
Why?
|
Nucleic Acid Heteroduplexes | 1 | 1993 | 46 | 0.030 |
Why?
|
Boston | 1 | 2007 | 9326 | 0.030 |
Why?
|
Necrosis | 2 | 1995 | 1611 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 1999 | 1206 | 0.030 |
Why?
|
Infusions, Intravenous | 5 | 2000 | 2219 | 0.030 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 4 | 2001 | 1741 | 0.030 |
Why?
|
Geography | 1 | 2016 | 656 | 0.030 |
Why?
|
Angioedemas, Hereditary | 1 | 2014 | 91 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1994 | 767 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1989 | 8547 | 0.030 |
Why?
|
Glycosylation | 1 | 1996 | 1098 | 0.030 |
Why?
|
Child | 9 | 2006 | 80153 | 0.030 |
Why?
|
Drug Therapy, Combination | 3 | 2016 | 6310 | 0.030 |
Why?
|
Protein Conformation | 1 | 2001 | 3968 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2018 | 1527 | 0.030 |
Why?
|
Lung Diseases | 1 | 1983 | 1909 | 0.030 |
Why?
|
Gene Expression | 3 | 2005 | 7581 | 0.030 |
Why?
|
Gemfibrozil | 1 | 1992 | 30 | 0.030 |
Why?
|
Placebos | 2 | 2007 | 1667 | 0.030 |
Why?
|
Abnormalities, Drug-Induced | 1 | 1995 | 339 | 0.030 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2012 | 26 | 0.030 |
Why?
|
Puerperal Disorders | 1 | 1995 | 299 | 0.030 |
Why?
|
Carrier Proteins | 2 | 1996 | 4936 | 0.030 |
Why?
|
Protein Folding | 1 | 1996 | 870 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2001 | 3734 | 0.030 |
Why?
|
Enkephalin, Methionine | 1 | 1991 | 26 | 0.020 |
Why?
|
Drug Eruptions | 1 | 1995 | 335 | 0.020 |
Why?
|
Fibrinogens, Abnormal | 1 | 1991 | 10 | 0.020 |
Why?
|
Multiple Organ Failure | 1 | 1994 | 387 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2425 | 0.020 |
Why?
|
Lipoproteins | 1 | 1996 | 881 | 0.020 |
Why?
|
Glutamine | 1 | 1994 | 577 | 0.020 |
Why?
|
Molecular Chaperones | 1 | 1996 | 754 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1723 | 0.020 |
Why?
|
RNA Splicing | 1 | 1996 | 918 | 0.020 |
Why?
|
Vincristine | 2 | 1984 | 1036 | 0.020 |
Why?
|
Environmental Pollutants | 1 | 2001 | 1277 | 0.020 |
Why?
|
Plasminogen Inactivators | 1 | 1990 | 37 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 161 | 0.020 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 1992 | 276 | 0.020 |
Why?
|
Phospholipids | 1 | 1995 | 786 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2003 | 2298 | 0.020 |
Why?
|
Syndrome | 1 | 1997 | 3267 | 0.020 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2012 | 190 | 0.020 |
Why?
|
Models, Molecular | 1 | 2001 | 5439 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 1997 | 1756 | 0.020 |
Why?
|
Receptors, Thrombin | 2 | 1987 | 130 | 0.020 |
Why?
|
Pandemics | 2 | 2020 | 8654 | 0.020 |
Why?
|
Postpartum Period | 1 | 2017 | 1173 | 0.020 |
Why?
|
Endoplasmic Reticulum | 1 | 1996 | 1134 | 0.020 |
Why?
|
Sequence Deletion | 1 | 1994 | 1494 | 0.020 |
Why?
|
Accreditation | 1 | 2013 | 473 | 0.020 |
Why?
|
DNA Primers | 1 | 1994 | 2819 | 0.020 |
Why?
|
Immune Sera | 1 | 1990 | 606 | 0.020 |
Why?
|
Chromogenic Compounds | 2 | 2002 | 31 | 0.020 |
Why?
|
Immunoglobulin G | 3 | 2018 | 4544 | 0.020 |
Why?
|
Peptides | 1 | 2002 | 4358 | 0.020 |
Why?
|
Critical Pathways | 1 | 2013 | 474 | 0.020 |
Why?
|
Hospitalization | 2 | 2020 | 10723 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 3 | 1992 | 1541 | 0.020 |
Why?
|
Cell Nucleus | 1 | 1998 | 2909 | 0.020 |
Why?
|
Calcium | 2 | 2001 | 5722 | 0.020 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 1995 | 1111 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1422 | 0.020 |
Why?
|
Postoperative Care | 3 | 2002 | 1468 | 0.020 |
Why?
|
Antibodies, Monoclonal | 4 | 1994 | 9177 | 0.020 |
Why?
|
Autoantibodies | 1 | 2018 | 2116 | 0.020 |
Why?
|
Uterine Cervicitis | 1 | 2008 | 31 | 0.020 |
Why?
|
Hot Temperature | 1 | 1995 | 1440 | 0.020 |
Why?
|
Models, Biological | 3 | 2008 | 9469 | 0.020 |
Why?
|
Plasminogen Activators | 2 | 1994 | 199 | 0.020 |
Why?
|
Logistic Models | 2 | 2020 | 13255 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2012 | 962 | 0.020 |
Why?
|
Dermatan Sulfate | 1 | 2008 | 43 | 0.020 |
Why?
|
Protein Binding | 4 | 2006 | 9351 | 0.020 |
Why?
|
Histidine | 1 | 1989 | 308 | 0.020 |
Why?
|
Kinetics | 4 | 2002 | 6374 | 0.020 |
Why?
|
Multicenter Studies as Topic | 2 | 2004 | 1702 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6484 | 0.020 |
Why?
|
Secondary Prevention | 2 | 2006 | 1475 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 1996 | 1974 | 0.020 |
Why?
|
Chondroitin Sulfates | 1 | 2008 | 174 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2019 | 5247 | 0.020 |
Why?
|
Pipecolic Acids | 1 | 2008 | 77 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2020 | 3807 | 0.020 |
Why?
|
Enzyme Precursors | 1 | 1987 | 170 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2012 | 1336 | 0.020 |
Why?
|
Child, Preschool | 4 | 2004 | 42230 | 0.020 |
Why?
|
Chemistry | 1 | 1987 | 347 | 0.020 |
Why?
|
Echocardiography | 1 | 2020 | 4989 | 0.020 |
Why?
|
Dogs | 2 | 1989 | 3839 | 0.020 |
Why?
|
Odds Ratio | 2 | 2010 | 9646 | 0.020 |
Why?
|
London | 1 | 2007 | 234 | 0.020 |
Why?
|
Protein Precursors | 1 | 1991 | 1132 | 0.020 |
Why?
|
Chemical Phenomena | 1 | 1987 | 507 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3745 | 0.020 |
Why?
|
Doxorubicin | 2 | 1984 | 2224 | 0.020 |
Why?
|
Chromosomes, Human, X | 1 | 2009 | 321 | 0.020 |
Why?
|
Upper Extremity | 1 | 2012 | 657 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 1989 | 750 | 0.020 |
Why?
|
Chromatography, Affinity | 2 | 1987 | 532 | 0.020 |
Why?
|
Cesarean Section | 2 | 2008 | 1396 | 0.020 |
Why?
|
Cysteine | 1 | 1991 | 891 | 0.020 |
Why?
|
Factor X Deficiency | 1 | 1986 | 8 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 1992 | 882 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 16981 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6425 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2013 | 1069 | 0.020 |
Why?
|
United States | 4 | 2021 | 72334 | 0.020 |
Why?
|
Patient Readmission | 1 | 2020 | 3270 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2009 | 6228 | 0.020 |
Why?
|
Cell Membrane | 1 | 1995 | 3688 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2008 | 492 | 0.020 |
Why?
|
Subarachnoid Hemorrhage, Traumatic | 1 | 2004 | 13 | 0.020 |
Why?
|
Mass Screening | 1 | 2001 | 5428 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 1979 | 2947 | 0.020 |
Why?
|
Albumins | 1 | 2007 | 575 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 1985 | 167 | 0.010 |
Why?
|
Catalysis | 2 | 2002 | 774 | 0.010 |
Why?
|
Gingival Diseases | 1 | 2004 | 36 | 0.010 |
Why?
|
Menopause | 1 | 1992 | 1646 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8830 | 0.010 |
Why?
|
Linkage Disequilibrium | 1 | 2009 | 1998 | 0.010 |
Why?
|
Cell Separation | 1 | 2009 | 1720 | 0.010 |
Why?
|
Premedication | 1 | 2004 | 246 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2265 | 0.010 |
Why?
|
Hematoma, Subdural | 1 | 2004 | 127 | 0.010 |
Why?
|
Laminectomy | 1 | 2004 | 225 | 0.010 |
Why?
|
Intracranial Thrombosis | 1 | 2004 | 108 | 0.010 |
Why?
|
Prednisolone | 1 | 1984 | 326 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2007 | 1596 | 0.010 |
Why?
|
Canada | 1 | 2009 | 2122 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13506 | 0.010 |
Why?
|
Research | 2 | 2007 | 1982 | 0.010 |
Why?
|
Preoperative Care | 2 | 2002 | 2242 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 2007 | 676 | 0.010 |
Why?
|
Hemorrhagic Disorders | 1 | 2002 | 34 | 0.010 |
Why?
|
Sterilization, Tubal | 1 | 2003 | 75 | 0.010 |
Why?
|
Amino Acid Sequence | 4 | 1991 | 13446 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1989 | 1844 | 0.010 |
Why?
|
Macaca fascicularis | 1 | 1984 | 903 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2009 | 1112 | 0.010 |
Why?
|
Cytarabine | 1 | 1984 | 697 | 0.010 |
Why?
|
Ear Diseases | 1 | 2004 | 180 | 0.010 |
Why?
|
Brain Infarction | 1 | 2004 | 290 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1983 | 11742 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 1994 | 3396 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2009 | 1667 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3606 | 0.010 |
Why?
|
Regression Analysis | 2 | 2002 | 6343 | 0.010 |
Why?
|
Life Expectancy | 1 | 2008 | 1242 | 0.010 |
Why?
|
Inheritance Patterns | 1 | 2004 | 341 | 0.010 |
Why?
|
Atherectomy, Coronary | 1 | 2001 | 137 | 0.010 |
Why?
|
Knee Prosthesis | 1 | 2004 | 395 | 0.010 |
Why?
|
Vinblastine | 1 | 1983 | 488 | 0.010 |
Why?
|
Endpoint Determination | 1 | 2004 | 590 | 0.010 |
Why?
|
Comorbidity | 2 | 2007 | 10508 | 0.010 |
Why?
|
Sepsis | 2 | 1993 | 2585 | 0.010 |
Why?
|
Splenectomy | 1 | 2003 | 391 | 0.010 |
Why?
|
Endotoxemia | 1 | 2002 | 196 | 0.010 |
Why?
|
Neopterin | 1 | 2001 | 56 | 0.010 |
Why?
|
Leucovorin | 1 | 1983 | 643 | 0.010 |
Why?
|
Smoking | 1 | 1998 | 9053 | 0.010 |
Why?
|
Thrombocythemia, Essential | 1 | 2002 | 113 | 0.010 |
Why?
|
Polycythemia Vera | 1 | 2002 | 161 | 0.010 |
Why?
|
Complement C1 Inactivator Proteins | 1 | 2000 | 89 | 0.010 |
Why?
|
Solubility | 1 | 2002 | 1091 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2014 | 18252 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 2004 | 520 | 0.010 |
Why?
|
ROC Curve | 2 | 2000 | 3579 | 0.010 |
Why?
|
Polymers | 1 | 1987 | 1617 | 0.010 |
Why?
|
Survival Analysis | 1 | 2012 | 10090 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3245 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2010 | 2220 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14666 | 0.010 |
Why?
|
Skin | 1 | 1993 | 4484 | 0.010 |
Why?
|
Bone Marrow | 1 | 1989 | 2911 | 0.010 |
Why?
|
Autoanalysis | 1 | 1999 | 71 | 0.010 |
Why?
|
Research Support as Topic | 1 | 2003 | 697 | 0.010 |
Why?
|
Molecular Weight | 3 | 1987 | 2186 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 1983 | 505 | 0.010 |
Why?
|
Family Health | 1 | 2004 | 1257 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1994 | 12795 | 0.010 |
Why?
|
Family Characteristics | 1 | 2004 | 1004 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1997 | 11903 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2001 | 778 | 0.010 |
Why?
|
Microspheres | 1 | 2001 | 784 | 0.010 |
Why?
|
Germany | 1 | 2001 | 875 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 384 | 0.010 |
Why?
|
Hip Prosthesis | 1 | 2004 | 921 | 0.010 |
Why?
|
Genetic Linkage | 1 | 2004 | 2341 | 0.010 |
Why?
|
Drug Interactions | 1 | 1983 | 1416 | 0.010 |
Why?
|
Sulfonamides | 1 | 2008 | 1978 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2013 | 4330 | 0.010 |
Why?
|
Infant, Newborn | 2 | 1995 | 26198 | 0.010 |
Why?
|
Leiomyoma | 1 | 2003 | 636 | 0.010 |
Why?
|
Hysterectomy | 1 | 2003 | 857 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 1983 | 2218 | 0.010 |
Why?
|
Vascular Diseases | 1 | 2005 | 1161 | 0.010 |
Why?
|
Drug Industry | 1 | 2003 | 788 | 0.010 |
Why?
|
Cisplatin | 1 | 1983 | 1651 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2002 | 2927 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1983 | 799 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 1985 | 1685 | 0.010 |
Why?
|
Methotrexate | 1 | 1983 | 1719 | 0.010 |
Why?
|
Volatilization | 1 | 1995 | 77 | 0.010 |
Why?
|
Biological Assay | 1 | 1999 | 626 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2019 | 13639 | 0.010 |
Why?
|
Factor Va | 1 | 1995 | 10 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2007 | 3826 | 0.010 |
Why?
|
Fracture Fixation, Internal | 1 | 2002 | 973 | 0.010 |
Why?
|
Dexamethasone | 1 | 1983 | 1948 | 0.010 |
Why?
|
Computer Simulation | 1 | 2009 | 6240 | 0.010 |
Why?
|
Protease Nexins | 1 | 1995 | 39 | 0.010 |
Why?
|
Aortic Diseases | 1 | 1981 | 735 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1985 | 2091 | 0.010 |
Why?
|
Blood Viscosity | 1 | 1995 | 124 | 0.010 |
Why?
|
Platelet Aggregation | 2 | 1991 | 771 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4575 | 0.010 |
Why?
|
Anus Diseases | 1 | 1994 | 55 | 0.010 |
Why?
|
Age Factors | 2 | 2008 | 18395 | 0.010 |
Why?
|
Environmental Monitoring | 1 | 2001 | 1460 | 0.010 |
Why?
|
Uterine Hemorrhage | 1 | 1995 | 240 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2003 | 1420 | 0.010 |
Why?
|
Lymphoma | 1 | 1983 | 1901 | 0.010 |
Why?
|
Phosphatidylserines | 1 | 1995 | 188 | 0.010 |
Why?
|
Fatigue | 1 | 2001 | 1552 | 0.010 |
Why?
|
Electrophoresis | 1 | 1993 | 227 | 0.010 |
Why?
|
Blood Volume | 1 | 1995 | 547 | 0.010 |
Why?
|
Hematocrit | 1 | 1995 | 623 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 1994 | 659 | 0.010 |
Why?
|
Phosphatidylcholines | 1 | 1995 | 405 | 0.010 |
Why?
|
Tooth Extraction | 1 | 1994 | 229 | 0.010 |
Why?
|
Respiratory Tract Infections | 1 | 2001 | 1010 | 0.010 |
Why?
|
Granulocytes | 1 | 1994 | 551 | 0.010 |
Why?
|
Fibrinopeptide B | 1 | 1991 | 4 | 0.010 |
Why?
|
Immunosorbent Techniques | 1 | 1992 | 175 | 0.010 |
Why?
|
Databases, Factual | 1 | 2007 | 7967 | 0.010 |
Why?
|
Delivery, Obstetric | 1 | 1979 | 940 | 0.010 |
Why?
|
Blood Loss, Surgical | 1 | 1995 | 637 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2004 | 5492 | 0.010 |
Why?
|
alpha-Macroglobulins | 1 | 1990 | 60 | 0.010 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 1994 | 495 | 0.010 |
Why?
|
Brain Ischemia | 1 | 2004 | 3049 | 0.010 |
Why?
|
Prekallikrein | 1 | 1990 | 11 | 0.010 |
Why?
|
Appendectomy | 1 | 1994 | 433 | 0.010 |
Why?
|
Fibrinolysin | 1 | 1990 | 131 | 0.010 |
Why?
|
Factor XII | 1 | 1990 | 19 | 0.010 |
Why?
|
Radiography | 1 | 2001 | 6965 | 0.010 |
Why?
|
Intraoperative Care | 1 | 1994 | 767 | 0.010 |
Why?
|
Mortality | 1 | 2001 | 2901 | 0.010 |
Why?
|
Electrocardiography | 1 | 2003 | 6377 | 0.010 |
Why?
|
Antithrombin Proteins | 1 | 1989 | 10 | 0.010 |
Why?
|
Crotalid Venoms | 1 | 1989 | 28 | 0.010 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1990 | 325 | 0.010 |
Why?
|
Vermont | 1 | 1989 | 81 | 0.010 |
Why?
|
Cysts | 1 | 1994 | 681 | 0.010 |
Why?
|
Methods | 1 | 1989 | 1067 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1991 | 1434 | 0.010 |
Why?
|
Trypsin | 1 | 1989 | 495 | 0.000 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1992 | 1693 | 0.000 |
Why?
|
Infant | 2 | 2004 | 36192 | 0.000 |
Why?
|
Depression, Chemical | 1 | 1987 | 184 | 0.000 |
Why?
|
Research Design | 1 | 2003 | 6180 | 0.000 |
Why?
|
Immunoelectrophoresis | 1 | 1987 | 94 | 0.000 |
Why?
|
Chronic Disease | 1 | 2002 | 9318 | 0.000 |
Why?
|
Cell Division | 1 | 1994 | 4465 | 0.000 |
Why?
|
Bone Marrow Cells | 1 | 1994 | 2416 | 0.000 |
Why?
|
Lymphocytes | 1 | 1994 | 2612 | 0.000 |
Why?
|
Half-Life | 1 | 1987 | 651 | 0.000 |
Why?
|
Cell Cycle | 1 | 1994 | 2932 | 0.000 |
Why?
|
Artifacts | 1 | 1995 | 1911 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16591 | 0.000 |
Why?
|
Cytokines | 1 | 2001 | 7396 | 0.000 |
Why?
|
Environmental Exposure | 1 | 2001 | 4486 | 0.000 |
Why?
|
Antibody Specificity | 1 | 1987 | 1060 | 0.000 |
Why?
|
Polymethacrylic Acids | 1 | 1985 | 32 | 0.000 |
Why?
|
Swine | 1 | 1995 | 5915 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2005 | 26125 | 0.000 |
Why?
|
Interleukin-6 | 1 | 1994 | 3208 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1983 | 550 | 0.000 |
Why?
|
Circadian Rhythm | 1 | 1995 | 2576 | 0.000 |
Why?
|
Mass Spectrometry | 1 | 1989 | 2192 | 0.000 |
Why?
|
Surface Properties | 1 | 1985 | 1161 | 0.000 |
Why?
|
Patient Compliance | 1 | 1992 | 2690 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2005 | 12148 | 0.000 |
Why?
|
Escherichia coli | 1 | 1994 | 4217 | 0.000 |
Why?
|
Endopeptidases | 1 | 1985 | 774 | 0.000 |
Why?
|
Liver Diseases | 1 | 1989 | 1298 | 0.000 |
Why?
|
Creatinine | 1 | 1985 | 1899 | 0.000 |
Why?
|
Infarction | 1 | 1981 | 248 | 0.000 |
Why?
|
Serine Endopeptidases | 1 | 1985 | 1022 | 0.000 |
Why?
|
Genes | 1 | 1983 | 1823 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7529 | 0.000 |
Why?
|
Intermittent Claudication | 1 | 1981 | 304 | 0.000 |
Why?
|
Aorta, Abdominal | 1 | 1981 | 625 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 1995 | 20098 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1994 | 22169 | 0.000 |
Why?
|
Renal Dialysis | 1 | 1985 | 1797 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1983 | 4615 | 0.000 |
Why?
|
Kidney Failure, Chronic | 1 | 1985 | 2471 | 0.000 |
Why?
|
Mice | 1 | 1994 | 81525 | 0.000 |
Why?
|
Kidney | 1 | 1981 | 7048 | 0.000 |
Why?
|